Study examines self-expanding plastic stents in the treatment of benign esophageal conditions

Jan 25, 2008

Researchers from Mayo Clinic in Rochester, Minnesota, recently examined the use of self-expanding plastic stents (SEPSs) in the treatment of benign esophageal disease and found that use of SEPSs resulted in frequent stent migration and few cases of long-term improvement. They concluded that further investigation is warranted to identify optimal patient populations and to guide future recommendations for the use of SEPSs. The study appears in the January issue of Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy.

Benign esophageal lesions such as strictures, perforations, and fistulae have a significant impact on patient well-being and are associated with the complications of malnutrition, pain, aspiration, respiratory decline, and death. In the past, the majority of refractory benign esophageal strictures were caused by chronic peptic irritation; however, with aggressive treatment of reflux disease, nonpeptic causes currently predominate. Esophageal stenting is a minimally invasive intervention that has been used as a treatment for expansion of stenoses and closure of perforations and fistulae. Self-expanding metal stents (SEMSs) are the current endoscopic standard for palliation of dysphagia resulting from malignant esophageal stenosis. SEMSs have also been used with variable success in the treatment of benign strictures.

Self-expanding plastic stents have been proposed for use in benign esophageal lesions because of their advantages over metallic stents, including lower cost, ease of placement and retrieval, and limited local tissue reaction while still providing alleviation of dysphagia. Previous reviews of the performance of SEPSs with limited numbers of patients have shown good success with resolution of benign stenosis and fistulae with few adverse effects.

“In our study of self-expanding plastic stents, migration occurred in more than 60 percent of all patients and of all stents placed,” said the study’s lead author Todd Baron, MD, FASGE, Mayo Clinic, Rochester. “Stent migration rates were not influenced by dilation at the time of stent placement or stent size. Although stent placement typically resolved the patient’s symptoms initially, long-term resolution was infrequent in our study group. Only six percent of all procedures provided long-term resolution of symptoms after stents were removed.”

Patients and Methods

This study was a retrospective review of cases of benign esophageal lesions in which a self-expanding nonmetallic Polyflex stent was placed at the Mayo Clinic, Rochester, from 2002 to 2006.

Thirty patients underwent at least one attempted SEPS placement. Nineteen patients were male and 11 were female, with an average age of 52.1 years. Twenty-two stents were placed in eight patients for benign strictures. Twenty-five stents were placed in 11 patients for anastomotic stricture after esophageal surgery. Twenty-two stents were placed in nine patients for esophageal fistulae or anastomotic leak. Fifteen stents were placed in five patients, and one stent placement was unsuccessful in one patient for radiation-induced strictures. A total of 83 stent placements were performed over the five-year period.

Overall, complications were minor and did not interfere with subsequent treatment. The most common initial complaints included chest pain, neck discomfort, and dysphagia (in 23 procedures) and nausea and vomiting (in eight procedures) and were managed with analgesic and antiemetic medications. Symptoms resolved within three days in most cases.

Results

Stents remained in place for an average of 53 days. Patients had symptomatic improvement initially in 77 of 83 stents placed (92.8 percent), three of 83 stents placed resulted in no symptom improvement, and three of 83 stents placed are awaiting follow up information. Stents were removed after several months if the patient’s symptoms remained alleviated or earlier if symptoms recurred, stent migration was noted, or complications developed. One stent was removed because of excessive granulation tissue formation. Migration was a frequent occurrence, noted in 18 of 29 patients (62.1 percent) and 53 of 83 stents placed (63.9 percent), whereas 21 of 83 stents placed remained in stable position (25.3 percent), four patients died with stents in place (unrelated to the stent), two patients have two stents still in place each, and one patient has a single stent still in place. These patients are awaiting follow-up.

Stent migration was typically accompanied by recurrence of symptoms and was noted more frequently in patients with proximal (30/44 stents, 68.2 percent) and distal (19/27 stents, 70.4 percent) esophageal lesions compared with mid-esophageal (3/10 stents, 30percent) location. Stent migration was defined either as radiographic evidence of the stent within the stomach or endoscopic visualization of the stent having moved from the initial placement location, or both. Success was defined as resolution of dysphagia and closure of the fistula or leak as seen on endoscopy or barium study.

Only six percent of procedures resulted in long-term symptom improvement at follow-up after the stent was removed, whereas 81.9 percent resulted in recurrence or persistence of symptoms.

Source: American Society for Gastrointestinal Endoscopy

Explore further: The impact of bacteria in our guts

add to favorites email to friend print save as pdf

Related Stories

HP sales inch up while profit drops

9 hours ago

Hewlett-Packard on Wednesday reported that its quarterly revenue was nudged up by improved computer sales, but its profit dropped as the veteran technology firm tried to renew its momentum.

Recommended for you

The impact of bacteria in our guts

18 hours ago

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

18 hours ago

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

19 hours ago

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0